Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · people with SCD
1 finding from 1 review
Total adverse events · Adults with acute asthma
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
1 finding from 1 review
Adverse events  · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review
Adverse effects of antibiotics: proportion of participants with one or more serious adverse event · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Cycled inhaled tobramycin (TNS) probably leads to lower adverse effects of antibiotics: proportion of participants with one… compared with culture‐based TNS (moderate certainty).
1 finding from 1 review